Skip to main
CYBN
CYBN logo

Cybin (CYBN) Stock Forecast & Price Target

Cybin (CYBN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cybin Inc. has demonstrated strong clinical execution and commercial groundwork, positioning the company favorably ahead of two significant readouts slated for 2026, indicating robust potential in the mental health therapeutics market. The completion of enrollment in the Phase 2 trial for generalized anxiety disorder (GAD) and ongoing advancements in the Phase 3 program for major depressive disorder (MDD) underscore Cybin’s commitment to progressing its innovative therapies. Additionally, the collaboration with ThermoFisher for manufacturing support and their integration into the Osmind clinic network exemplify Cybin's strategic initiatives aimed at enhancing operational efficiency and market readiness.

Bears say

The financial outlook on Cybin Inc. is negatively impacted by several fundamental risks associated with the development of neuropsychiatric therapies, including the potential for clinical trial failures and the unproven safety and efficacy of its proprietary psychedelic compounds. Changes in the discounted cash flow (DCF) model, primarily due to recent dilution from capital raises, have led to a significant reduction in the company's price target, which signals concerns over its financial health and future profitability. Additionally, challenges related to regulatory approval, intellectual property protection, and the commercialization of its products further compound the uncertainty surrounding Cybin's ability to succeed in a highly competitive biopharmaceutical market.

Cybin (CYBN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cybin (CYBN) Forecast

Analysts have given Cybin (CYBN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cybin (CYBN) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cybin (CYBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.